Bousser, M G <br/><br/>
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.  [electronic resource] 

 -  Cerebrovascular diseases (Basel, Switzerland)  2009 
 - 509-18 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1421-9786 
<br/><br/><label>Standard No.: </label>10.1159/000212671  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Aspirin--adverse effects<br/>Cardiovascular Diseases--etiology<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Endpoint Determination<br/>Female<br/>Humans<br/>International Cooperation<br/>Ischemic Attack, Transient--complications<br/>Male<br/>Middle Aged<br/>Naphthalenes--adverse effects<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Propionates--adverse effects<br/>Receptors, Thromboxane--antagonists & inhibitors<br/>Stroke--complications<br/>Treatment Outcome